Results 121 to 130 of about 47,983 (211)

PD-L1-Guided Chemo-Immunotherapy in Advanced Triple-Negative Breast Cancer: A Meta-Analysis of Survival Benefits and Toxicity Profiles. [PDF]

Cancers (Basel)
Nan L, Zuo X, Yin X, Li H, Wang Y, Wang X, Chen D, Zhang G.   +7 more
europepmc   +1 more source

Real-World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular Subtypes. [PDF]

Cancer Med
Zhou H, Chen L, Lu Q, Wu H, Jiang K, Xu F, Wang S.   +6 more
europepmc   +1 more source

Real-world outcomes of pembrolizumab in advanced anal cancer: a nationwide Danish anal Cancer Group report. [PDF]

Acta Oncol
Garm Spindler KL, Hvid CA, Fokdal LU, Wind KL, Jakobsen AV, Eefsen RL, Serup-Hansen E.   +6 more
europepmc   +1 more source

Evaluating beta-tubulin variants as predictors of benzimidazole resistance across Caenorhabditis nematodes. [PDF]

PLoS Pathog
Shaver AO, McKeown R, Reyes Otero JM, Collins JB, Hogan DW, Fraser JS, Dreyer SM, Ragsdale EJ, Andersen EC.   +8 more
europepmc   +1 more source

Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study. [PDF]

In Vivo
Karabuga B, Büyükkör M, Karaçin C, Karabuga EK, Yildiz S, Güneysu GG, Akgüner G, Uzundere FK, Arslan A, Davarci SE, Urakçi Z, Sütçüoğlu O, Yildirim ÖA, Karadurmuş N, Ergün Y.   +14 more
europepmc   +1 more source

Coordinated regulation of Capping Protein by CARMIL and V-1/myotrophin. [PDF]

J Biol Chem
Hammer JA, Cooper JA.
europepmc   +1 more source

The Impact of the hsCRP/BMI Ratio on Cardiovascular Outcomes in CAD Patients: A Population-Based Study. [PDF]

Mediators Inflamm
Liu D, Wang X, Zhang K, Meng X, Wang J, Yang J, Gao J, Wang Y, Wen J, Li C, Zheng M, Liu G, Ma Y, Wang W, Tang YD, Shao C.   +15 more
europepmc   +1 more source

Quantitative analysis of light-induced ion segregation in mixed-halide perovskites. [PDF]

J Appl Crystallogr
Machovec P, Horák L, Dopita M, Neykova N, Landová L, Holovský J, Holý V.   +6 more
europepmc   +1 more source

Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR⁺/HER2^- advanced breast cancer. [PDF]

Am J Cancer Res
Hou B, Zhang Y.
europepmc   +1 more source